SELLAS Life Sciences Group, Inc. Deferred State and Local Income Tax Expense (Benefit)
SELLAS Life Sciences Group, Inc. (SLS) reported Deferred State and Local Income Tax Expense (Benefit) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2023-03-16
- SELLAS Life Sciences Group, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was $0.00.
- SELLAS Life Sciences Group, Inc. deferred state and local income tax expense (benefit) for fiscal 2021 was $0.00.
- SELLAS Life Sciences Group, Inc. deferred state and local income tax expense (benefit) for fiscal 2020 was -$22.00K, a 200.00% decline from fiscal 2019.
- SELLAS Life Sciences Group, Inc. deferred state and local income tax expense (benefit) for fiscal 2019 was $22.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | |
| 2020-12-31 | -$22.00K 10-K · filed 2022-03-31 | |
| 2019-12-31 | $22.00K 10-K · filed 2021-03-23 | |
| 2018-12-31 | -$570.00K 10-K · filed 2020-03-13 | |
| 2017-12-31 | $39.00K 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$41.00K 10-K · filed 2018-04-13 | $33.00K 10-K · filed 2017-03-15 |
| 2015-12-31 | $33.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 | |
| 2013-12-31 | $158.00K 10-K/A · filed 2016-04-15 | |
| 2012-12-31 | -$158.00K 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |